Alessandro Bonardi

Dr. Alessandro Bonardi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ABAlessandro Bonardi
Alessandro Bonardi
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
SBSilvia Bua
Silvia Bua
JCJacob Combs
Jacob Combs
CLCarrie Lomelino
Carrie Lomelino
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
The “tail approach” has become a milestone in human carbonic anhydrase inhibitor (hCAI) design for various therapeutics, including antiglaucoma agents. Besides the classical hydrophobic/hydrophilic division of hCAs active site, several subpockets have been identified at the middle/outer active sites rim, which could be targeted to increase the CAI isoform selectivity. This postulate is explored here by three-tailed benzenesulfonamide CAIs (TTI) to fully exploit such amino acid differences among hCAs. In this proof-of-concept study, an extensive structure–activity relationship (SAR) study was carried out with 32 such benzenesulfonamides differing in tails combination that were assayed for hCAs I, II, IV, and XII inhibition. A structural study was undertaken by X-ray crystallography and in silico tools to assess the ligand/target interaction mode. The most active and selective inhibitors against isoforms implicated in glaucoma were assessed in a rabbit model of the disease achieving an intraocular pressure-lowering action comparable to the clinically used dorzolamide.


1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
MAMahmoud F. Abo-Ashour
Mahmoud F. Abo-Ashour
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
RERadwan S. El-Haggar
Radwan S. El-Haggar
SBSilvia Bua
Silvia Bua
Claudiu SupuranClaudiu Supuran
Claudiu Supuran

1 January 2018 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
ABAlessandro Bonardi
Alessandro Bonardi
Paola GratteriPaola Gratteri
Paola Gratteri
Bruno CerraBruno Cerra
Bruno Cerra
AGAntimo Gioiello
Antimo Gioiello
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
Bile acids have been shown to inhibit human (h) carbonic anhydrases (CA, EC 4.2.1.1) along the gastrointestinal tract, including hCA II. The elucidation of the hormonal inhibition mechanism of the bile acid cholate to hCA II was provided in 2014 by X-ray crystallography. Herein, we extend the inhibition study to a wealth of steroids against four relevant hCA isoforms. Steroids displaying pendants and functional groups of the carboxylate, phenolic or sulfonate types appended at the tetracyclic ring were shown to inhibit the cytosolic CA II and the tumor-associated, transmembrane CA IX in a medium micromolar range (38.9–89.9 µM). Docking studies displayed the different chemotypes CA inhibition mechanisms. Molecular dynamics (MD) gave insights on the stability over time of hyocholic acid binding to CA II.

1 February 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAlessandro Bonardi
Alessandro Bonardi
MFMatteo Falsini
Matteo Falsini
Daniela CatarziDaniela Catarzi
Daniela Catarzi
Flavia VaranoFlavia Varano
Flavia Varano
Lorenzo Di Cesare MannelliLorenzo Di Cesare Mannelli
Lorenzo Di Cesare Mannelli
Vittoria ColottaVittoria Colotta
Vittoria Colotta

Verified
Journal Article
Open access
PDF file
Rossella GrandeRossella Grande
Rossella Grande
Simone CarradoriSimone Carradori
Simone Carradori
VPValentina Puca
Valentina Puca
IVIrene Vitale
Irene Vitale
AAAndrea Angeli
Andrea Angeli
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
Helicobacter pylori, a Gram-negative neutrophilic pathogen, is the cause of chronic gastritis, peptic ulcers, and gastric cancer in humans. Current therapeutic regimens suffer from an emerging bacterial resistance rate and poor patience compliance. To improve the discovery of compounds targeting bacterial alternative enzymes or essential pathways such as carbonic anhydrases (CAs), we assessed the anti-H. pylori activity of thymol and carvacrol in terms of CA inhibition, isoform selectivity, growth impairment, biofilm production, and release of associated outer membrane vesicles-eDNA. The microbiological results were correlated by the evaluation in vitro of H. pylori CA inhibition, in silico analysis of the structural requirements to display such isoform selectivity, and the assessment of their limited toxicity against three probiotic species with respect to amoxicillin. Carvacrol and thymol could thus be considered as new lead compounds as alternative H. pylori CA inhibitors or to be used in association with current drugs for the management of H. pylori infection and limiting the spread of antibiotic resistance.